13,432 Shares in LeMaitre Vascular, Inc. (NASDAQ:LMAT) Purchased by Illumine Investment Management LLC

Illumine Investment Management LLC acquired a new position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 13,432 shares of the medical instruments supplier’s stock, valued at approximately $1,238,000.

Other large investors also recently bought and sold shares of the company. KBC Group NV increased its holdings in LeMaitre Vascular by 58.4% in the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier’s stock worth $102,000 after buying an additional 410 shares in the last quarter. Empowered Funds LLC bought a new stake in LeMaitre Vascular in the 4th quarter worth about $150,000. SG Americas Securities LLC bought a new stake in LeMaitre Vascular in the 4th quarter worth about $158,000. Advisors Asset Management Inc. boosted its position in LeMaitre Vascular by 180.2% in the third quarter. Advisors Asset Management Inc. now owns 1,852 shares of the medical instruments supplier’s stock worth $172,000 after purchasing an additional 1,191 shares during the last quarter. Finally, Sanctuary Advisors LLC purchased a new position in LeMaitre Vascular in the third quarter worth about $181,000. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Stock Down 3.0 %

LMAT stock opened at $99.91 on Friday. LeMaitre Vascular, Inc. has a twelve month low of $62.39 and a twelve month high of $109.58. The stock has a market cap of $2.25 billion, a P/E ratio of 54.60, a PEG ratio of 2.22 and a beta of 0.96. The business’s 50-day moving average price is $96.90 and its 200-day moving average price is $94.66.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.49. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm had revenue of $55.81 million for the quarter, compared to analysts’ expectations of $55.99 million. On average, equities research analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

LMAT has been the topic of several research reports. Barrington Research raised their target price on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. Oppenheimer reissued an “outperform” rating and issued a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Wells Fargo & Company initiated coverage on LeMaitre Vascular in a research report on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 target price on the stock. Finally, StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $94.63.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.